» Articles » PMID: 31628728

Effect of Blood Flow on Platelets, Leukocytes, and Extracellular Vesicles in Thrombosis of Simulated Neonatal Extracorporeal Circulation

Overview
Publisher Elsevier
Specialty Hematology
Date 2019 Oct 20
PMID 31628728
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Extracorporeal membrane oxygenation (ECMO) has frequent and sometimes lethal thrombotic complications. The role that activated platelets, leukocytes, and small (0.3-micron to 1-micron) extracellular vesicles (EVs) play in ECMO thrombosis is not well understood.

Objectives: To test the effect of blood flow rate on the generation of activated platelets, leukocytes, and EVs in a simulated neonatal ECMO circuit using heparinized human whole blood.

Methods: Simulated neonatal roller pump circuits circulated whole blood at low, nominal, and high flow rates (0.3, 0.5, and 0.7 L/min) for 6 h. Coagulopathy was defined by thromboelastography (TEG), STA -procoagulant phospholipid clot time (STA Procoag-PPL), and calibrated automated thrombogram. High-resolution flow cytometry measured the cellular expression of prothrombotic phospholipids and proteins on platelets, leukocytes, and EV.

Results: Despite heparinization, occlusive thrombosis halted flow in two of five circuits at 0.3 L/min and three of five circuits at 0.7 L/min. None of the five circuits at 0.5 L/min exhibited occlusive thrombosis. Phosphatidylserine (PS)-positive platelets and EVs increased at all flow rates more than blood under static conditions (P < .0002). Tissue factor (TF)-positive leukocytes and EVs increased only in low-flow and high-flow circuits (P < .0001). Tissue factor pathway inhibitor (TFPI), at 50 times more than the concentration in healthy adults, failed to suppress thrombin initiation in low-flow and high-flow circuits.

Conclusions: This in vitro study informs ECMO specialists to avoid low and high blood flow that increases TF expression on leukocytes and EVs, which likely initiate clot formation. Interventions to decrease TF generated by ECMO may be an effective approach to decrease thrombosis.

Citing Articles

Recent Advances and Future Directions in Extracorporeal Carbon Dioxide Removal.

Lamas T, Fernandes S, Vasques F, Karagiannidis C, Camporota L, Barrett N J Clin Med. 2025; 14(1.

PMID: 39797096 PMC: 11722077. DOI: 10.3390/jcm14010012.


Heparin Resistance in Patients Receiving Extracorporeal Membrane Oxygenation: A Review.

Li T, Zhailauova A, Kuanyshbek A, Wachruschew I, Tulegenov S, Sazonov V J Clin Med. 2025; 13(24.

PMID: 39768556 PMC: 11728406. DOI: 10.3390/jcm13247633.


Management of Bleeding and Thrombotic Complications During Pediatric Extracorporeal Membrane Oxygenation: The Pediatric Extracorporeal Membrane Oxygenation Anticoagulation CollaborativE Consensus Conference.

Rintoul N, McMichael A, Bembea M, DiGeronimo R, Patregnani J, Alexander P Pediatr Crit Care Med. 2024; 25(7 Suppl 1):e66-e77.

PMID: 38959361 PMC: 11216396. DOI: 10.1097/PCC.0000000000003489.


The Role of Extracorporeal Membrane Oxygenation ECMO in Accidental Hypothermia and Rewarming in Out-of-Hospital Cardiac Arrest Patients-A Literature Review.

Hymczak H, Golab A, Kosinski S, Podsiadlo P, Sobczyk D, Drwila R J Clin Med. 2023; 12(21).

PMID: 37959196 PMC: 10649291. DOI: 10.3390/jcm12216730.


Factor XI Inhibition With Heparin Reduces Clot Formation in Simulated Pediatric Extracorporeal Membrane Oxygenation.

Meyer A, Thorpe C, Fraker T, Cancio T, Rocha J, Willis R ASAIO J. 2023; 69(12):1074-1082.

PMID: 37801726 PMC: 10841048. DOI: 10.1097/MAT.0000000000002048.


References
1.
Wendel H, Philipp A, Weber N, Birnbaum D, Ziemer G . Oxygenator thrombosis: worst case after development of an abnormal pressure gradient--incidence and pathway. Perfusion. 2001; 16(4):271-8. DOI: 10.1177/026765910101600402. View

2.
Kappelmayer J, Bernabei A, EDMUNDS Jr L, Edgington T, Colman R . Tissue factor is expressed on monocytes during simulated extracorporeal circulation. Circ Res. 1993; 72(5):1075-81. DOI: 10.1161/01.res.72.5.1075. View

3.
Biro E, Sturk-Maquelin K, Vogel G, Meuleman D, Smit M, Hack C . Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost. 2004; 1(12):2561-8. DOI: 10.1046/j.1538-7836.2003.00456.x. View

4.
Ollivier V, Wang J, Manly D, Machlus K, Wolberg A, Jandrot-Perrus M . Detection of endogenous tissue factor levels in plasma using the calibrated automated thrombogram assay. Thromb Res. 2009; 125(1):90-6. PMC: 2826585. DOI: 10.1016/j.thromres.2009.03.003. View

5.
Burger D, Schock S, Thompson C, Montezano A, Hakim A, Touyz R . Microparticles: biomarkers and beyond. Clin Sci (Lond). 2012; 124(7):423-41. DOI: 10.1042/CS20120309. View